Methicillin-resistant Staphylococcus aureus (MRSA) is a persistent challenge in veterinary medicine, with rising concerns over antimicrobial resistance (AMR) and limited treatment options.
This laboratory research study, conducted by the Luxembourg Institute of Science and Technology (LIST), evaluated the efficacy of Provilan Wound Care (now rebranded Dermo Care) Spray in reducing MRSA using probiotics.
The study demonstrated a 99% reduction in MRSA colony-forming units (CFU) within 22 hours, achieved without antibiotics or contributing to AMR.
The research confirmed that probiotics in Provilan Dermo Care Spray inhibit MRSA by outcompeting harmful bacteria and restoring microbial balance.
The product's efficacy was validated under real-life conditions, with results showing no reduction in MRSA when probiotics were absent from the formula.
These findings highlight the potential of Provilan Dermo Care Spray as a sustainable and non-invasive, non-medicinal supportive therapy for managing infections and wounds in animals. This aligns with the growing need for AMR-free solutions in veterinary medicine.
Key Takeaways for Veterinary Practice
- Mechanical Action
Probiotics inhibit MRSA by outcompeting harmful bacteria for resources, restoring microbial balance on the skin.
- Potential for Clinical Integration
This study highlights the potential of application of non-medicinal probiotic spray for managing wounds and preventing infections in veterinary practice.
- Sustainability and Innovation
A non-invasive and sustainable mechanism that aligns with global efforts to
reduce antibiotic use and reduce antimicrobial resistance in veterinary medicine.
Note: This case study references the product previously branded as LUCAA+ Wound Care, now available under the Provilan Vet Dermo Care brand. The formulation remains unchanged, ensuring the same trusted results for
veterinary professionals.
